<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01205035</url>
  </required_header>
  <id_info>
    <org_study_id>FVF4875s</org_study_id>
    <nct_id>NCT01205035</nct_id>
  </id_info>
  <brief_title>High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia</brief_title>
  <acronym>HD-LIPT</acronym>
  <official_title>High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia [HD-LIPT]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye Center of Northern Colorado, P.C.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eye Center of Northern Colorado, P.C.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic Parafoveal Telangiectasia (IPT) [also known as Idiopathic Perifoveal&#xD;
      Telangiectasia, Idiopathic Juxtafoveal Telangiectasia (IJT, JFT) and Macular Telangiectasia&#xD;
      (MacTel)] is a disorder of unknown etiology. IPT is classified as Group 2A in the Gass&#xD;
      classification of macular telangiectasias (Reference 1,5) - a bilateral, but not always&#xD;
      symmetric disorder. It is characterized in its early stages by dilation and loss of&#xD;
      parafoveal capillaries accompanied by angiographic leakage, &quot;right angle&quot; venules, central&#xD;
      and parafoveal intraretinal cysts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DESCRIPTION OF THE STUDY&#xD;
&#xD;
      This is an open-label, Phase I/II study of intravitreally administered ranibizumab in&#xD;
      subjects with nonproliferative Idiopathic Parafoveal Telangiectasia (IPT).&#xD;
&#xD;
      Consented, enrolled subjects will be randomized into two groups: observation and treatment.&#xD;
      The observation group will be monitored monthly while the treatment group will receive three&#xD;
      open-label intravitreal injections of 1.0 mg ranibizumab administered every 30 days for 3&#xD;
      months and then as needed monthly, based on defined criteria. NOTE: The original protocol had&#xD;
      the treatment group dosed at 2.0 mg/0.05mL. However, the 2.0mg dose will become unavailable&#xD;
      beginning January 31, 2012. Therefore, the protocol amendment submitted in December 2011&#xD;
      changed the 2.0mg arm to a 1.0mg/ 0.10mL arm. Please note that three patients were already&#xD;
      treated with 2.0mg before the amendment was submitted, so they will be switched to 1.0mg if&#xD;
      they have not completed the study when the 2.0 dose is no longer available in January 2012.&#xD;
&#xD;
      Protocol: FVF4875s Final 6/P&#xD;
&#xD;
      29MAR2010&#xD;
&#xD;
      3.2&#xD;
&#xD;
      RATIONALE FOR STUDY DESIGN&#xD;
&#xD;
      As IPT is a chronically progressive condition, the purpose of this study is to see if&#xD;
      high-dose ranibizumab can slow or stop the leakage and growth of existing, dilated, macular&#xD;
      vessels in cases where no co-existing neovascularization exists as defined by fluorescein&#xD;
      angiography and Ocular Coherence Tomography (OCT). Other outcomes include stabilization of&#xD;
      visual acuity compared to observation group (defined by best corrected Early Treatment&#xD;
      Diabetic Retinopathy Study (ETDRS) measurements), and changes in ultrastructural features, as&#xD;
      defined by OCT,&#xD;
&#xD;
      3.3&#xD;
&#xD;
      OUTCOME MEASURES&#xD;
&#xD;
      3.3.1 Primary Outcome Measures&#xD;
&#xD;
      To compare the change in visual acuity from baseline to one year in patients with&#xD;
      nonproliferative IPT who are either treated with high-dose (1.0mg) ranibizumab or observed.&#xD;
&#xD;
      3.3.2 Secondary Outcome Measures&#xD;
&#xD;
      i. To compare the change in visual acuity from baseline to 6 months and 9 months in patients&#xD;
      with nonproliferative IPT who are either treated with high- dose (1.0mg) ranibizumab or&#xD;
      observed.&#xD;
&#xD;
      ii. To assess OCT changes in standard Central Subfield Thickness (CST) from baseline to 6&#xD;
      months, 9 months and 12 months.&#xD;
&#xD;
      iii. To assess safety of administering 1.0mg ranibizumab (Lucentis) in patients with&#xD;
      nonproliferative IPT at 6 months, 9 months and 12 months.&#xD;
&#xD;
      iv. To assess changes in angiographic leakage from baseline at 6 and 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity Change From Baseline to Month 12 of the Study</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Acuity From Baseline to Month 6 and From Baseline to 9 Months</measure>
    <time_frame>Baseline to 6 months and baseline to 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Standard Central Subfield Thickness (CST) as Measured by OCT From Baseline to 6, 9, and 12 Months</measure>
    <time_frame>Baseline to 6, 9, and 12 months</time_frame>
    <description>A large decrease in CST thickness may be indicative of a worse clinical outcome. These measurements are done to ensure safety of the participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events Associated to the Administration of Ranibizumab 2.0mg</measure>
    <time_frame>Baseline to 6 month, baseline to 9 month and baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Leakage From Baseline to Month 6 and 12</measure>
    <time_frame>Baseline to 6 and baseline to 12 months</time_frame>
    <description>Angiography was taken via fluorescein angiography. Any increases of angiographic leakage was counted between baseline and month 6. Also any decreases of angiographic leakage was counted between baseline and 6 month. The same was done between baseline and 12 month.&#xD;
Any increase of angiographic leakage was counted as a +1. Likewise, any decrease of angiographic leakage was counted as a -1. The sum was calculated based on the number of participants in each arm and the total shown in the outcome. For example: if across the three injected participants for their 6 month visit, two of them showed an increase of angiographic leakage and one showed a decrease, then the outcome would be, (+1) + (+1) + (-1)= +1. Likewise, if the same three participant's 12 month visit showed two with a decrease in leakage and one with no changes in leakage, the outcome would be, (-1) + (-1) + (0)= -2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Retinal Diseases</condition>
  <condition>Telangiectasis</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation; No treatment given</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravitreal ranibizumab 2.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial dose 2.0mg switched to 1.0mg at near conclusion of study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab 2.0mg</intervention_name>
    <description>Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections</description>
    <arm_group_label>Intravitreal ranibizumab 2.0mg</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide written informed consent and comply with study assessments for the&#xD;
             full duration of the study&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Presence of nonproliferative IPT confirmed by fluorescein angiography and&#xD;
             spectral-domain OCT&#xD;
&#xD;
          -  Age greater than 18&#xD;
&#xD;
          -  Vision equal to or worse than 20/25 and better than or equal to 20/400 by ETDRS chart,&#xD;
             without co-existing choroidal neovascularization.&#xD;
&#xD;
          -  Physical ability and reasonable expectation to maintain all follow-up appointments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy (positive pregnancy test) or lactation&#xD;
&#xD;
          -  Premenopausal women not using adequate contraception. The following are considered&#xD;
             effective means of contraception: surgical sterilization or use of oral&#xD;
             contraceptives, barrier contraception with either a condom or diaphragm in conjunction&#xD;
             with spermicidal gel, an IUD, or contraceptive hormone implant or patch.&#xD;
&#xD;
          -  Any other condition that the investigator believes would pose a significant hazard to&#xD;
             the subject if the investigational therapy were initiated&#xD;
&#xD;
          -  Participation in another simultaneous ophthalmologic investigation or trial&#xD;
&#xD;
          -  Any patient with proliferative diabetic retinopathy, diabetic macular edema, uveitis,&#xD;
             history of ocular trauma, severe glaucoma, neovascular age-related macular&#xD;
             degeneration&#xD;
&#xD;
          -  Duration of previous treatment of IPT that exceeds two years.&#xD;
&#xD;
          -  Any concurrent intraocular condition in the study eye (e.g., cataract or diabetic&#xD;
             retinopathy) that, in the opinion of the investigator, could either:&#xD;
&#xD;
          -  Require medical or surgical intervention during the 12-month study period to prevent&#xD;
             or treat visual loss that might result from that condition, or&#xD;
&#xD;
          -  If allowed to progress untreated, could likely contribute to loss of at least 2&#xD;
             Snellen equivalent lines of Best Corrected Visual Acuity (BCVA) over the study period&#xD;
&#xD;
          -  Prior/Concomitant Treatment:&#xD;
&#xD;
          -  Previous steroids (oral) within 30 days preceding Day 0&#xD;
&#xD;
          -  Previous participation in any studies of investigational drugs within 30 days&#xD;
             preceding Day 0 (excluding vitamins and minerals)&#xD;
&#xD;
          -  Prior participation in a Genentech ranibizumab clinical trial within 60 days.&#xD;
&#xD;
          -  History of receiving intravitreal injections of ranibizumab, bevacizumab, pegaptanib,&#xD;
             or any other intravitreal medication within 60 days of first injection. History of&#xD;
             receiving intravitreal or subtenons triamcinolone within 90 days of first injection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur Korotkin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye Center of Northern Colorado</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye Center of Northern Colorado</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>September 16, 2010</study_first_submitted>
  <study_first_submitted_qc>September 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2010</study_first_posted>
  <results_first_submitted>March 18, 2015</results_first_submitted>
  <results_first_submitted_qc>March 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 10, 2015</results_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eye Center of Northern Colorado, P.C.</investigator_affiliation>
    <investigator_full_name>Arthur Korotkin, M.D.</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Idiopathic Parafoveal Telangiectasia</keyword>
  <keyword>Macular Telangiectasia</keyword>
  <keyword>Macula Lutea/pathology</keyword>
  <keyword>Retinal Diseases/pathology</keyword>
  <keyword>Retinal Pigments/metabolism</keyword>
  <keyword>Telangiectasis/metabolism</keyword>
  <keyword>Telangiectasis/pathology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Telangiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Observation</title>
          <description>Observation; No treatment given</description>
        </group>
        <group group_id="P2">
          <title>Intravitreal Ranibizumab 2.0mg</title>
          <description>Initial dose 2.0mg switched to 1.0mg at near conclusion of study.&#xD;
ranibizumab 2.0mg: Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Observation</title>
          <description>Observation; No treatment given</description>
        </group>
        <group group_id="B2">
          <title>Intravitreal Ranibizumab 2.0mg</title>
          <description>Initial dose 2.0mg switched to 1.0mg at near conclusion of study.&#xD;
ranibizumab 2.0mg: Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="52" upper_limit="76"/>
                    <measurement group_id="B2" value="65" lower_limit="52" upper_limit="76"/>
                    <measurement group_id="B3" value="66.5" lower_limit="52" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity Change From Baseline to Month 12 of the Study</title>
        <time_frame>Baseline to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observation</title>
            <description>Observation; No treatment given</description>
          </group>
          <group group_id="O2">
            <title>Intravitreal Ranibizumab 2.0mg</title>
            <description>Initial dose 2.0mg switched to 1.0mg at near conclusion of study.&#xD;
ranibizumab 2.0mg: Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity Change From Baseline to Month 12 of the Study</title>
          <units>LogMAR Unit</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.1" upper_limit="0.1"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-0.12" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Visual Acuity From Baseline to Month 6 and From Baseline to 9 Months</title>
        <time_frame>Baseline to 6 months and baseline to 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observation</title>
            <description>Observation; No treatment given</description>
          </group>
          <group group_id="O2">
            <title>Intravitreal Ranibizumab 2.0mg</title>
            <description>Initial dose 2.0mg switched to 1.0mg at near conclusion of study.&#xD;
ranibizumab 2.0mg: Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Acuity From Baseline to Month 6 and From Baseline to 9 Months</title>
          <units>LogMAR Unit</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 6 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.04" upper_limit="0.04"/>
                    <measurement group_id="O2" value="-0.10" lower_limit="-0.2" upper_limit="-0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 9 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" lower_limit="0.02" upper_limit="0.02"/>
                    <measurement group_id="O2" value="-0.12" lower_limit="-0.14" upper_limit="-0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Standard Central Subfield Thickness (CST) as Measured by OCT From Baseline to 6, 9, and 12 Months</title>
        <description>A large decrease in CST thickness may be indicative of a worse clinical outcome. These measurements are done to ensure safety of the participants.</description>
        <time_frame>Baseline to 6, 9, and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observation</title>
            <description>Observation; No treatment given</description>
          </group>
          <group group_id="O2">
            <title>Intravitreal Ranibizumab 2.0mg</title>
            <description>Initial dose 2.0mg switched to 1.0mg at near conclusion of study.&#xD;
ranibizumab 2.0mg: Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Standard Central Subfield Thickness (CST) as Measured by OCT From Baseline to 6, 9, and 12 Months</title>
          <description>A large decrease in CST thickness may be indicative of a worse clinical outcome. These measurements are done to ensure safety of the participants.</description>
          <units>Micrometer</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 6 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20" lower_limit="-20" upper_limit="-20"/>
                    <measurement group_id="O2" value="7" lower_limit="-2" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 9 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16" lower_limit="-16" upper_limit="-16"/>
                    <measurement group_id="O2" value="-6" lower_limit="-17" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11" lower_limit="-11" upper_limit="-11"/>
                    <measurement group_id="O2" value="-4" lower_limit="-14" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events Associated to the Administration of Ranibizumab 2.0mg</title>
        <time_frame>Baseline to 6 month, baseline to 9 month and baseline to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observation</title>
            <description>Observation; No treatment given</description>
          </group>
          <group group_id="O2">
            <title>Intravitreal Ranibizumab 2.0mg</title>
            <description>Initial dose 2.0mg switched to 1.0mg at near conclusion of study.&#xD;
ranibizumab 2.0mg: Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events Associated to the Administration of Ranibizumab 2.0mg</title>
          <units>Number of Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 6 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 9 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiographic Leakage From Baseline to Month 6 and 12</title>
        <description>Angiography was taken via fluorescein angiography. Any increases of angiographic leakage was counted between baseline and month 6. Also any decreases of angiographic leakage was counted between baseline and 6 month. The same was done between baseline and 12 month.&#xD;
Any increase of angiographic leakage was counted as a +1. Likewise, any decrease of angiographic leakage was counted as a -1. The sum was calculated based on the number of participants in each arm and the total shown in the outcome. For example: if across the three injected participants for their 6 month visit, two of them showed an increase of angiographic leakage and one showed a decrease, then the outcome would be, (+1) + (+1) + (-1)= +1. Likewise, if the same three participant's 12 month visit showed two with a decrease in leakage and one with no changes in leakage, the outcome would be, (-1) + (-1) + (0)= -2</description>
        <time_frame>Baseline to 6 and baseline to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observation</title>
            <description>Observation; No treatment given</description>
          </group>
          <group group_id="O2">
            <title>Intravitreal Ranibizumab 2.0mg</title>
            <description>Initial dose 2.0mg switched to 1.0mg at near conclusion of study.&#xD;
ranibizumab 2.0mg: Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographic Leakage From Baseline to Month 6 and 12</title>
          <description>Angiography was taken via fluorescein angiography. Any increases of angiographic leakage was counted between baseline and month 6. Also any decreases of angiographic leakage was counted between baseline and 6 month. The same was done between baseline and 12 month.&#xD;
Any increase of angiographic leakage was counted as a +1. Likewise, any decrease of angiographic leakage was counted as a -1. The sum was calculated based on the number of participants in each arm and the total shown in the outcome. For example: if across the three injected participants for their 6 month visit, two of them showed an increase of angiographic leakage and one showed a decrease, then the outcome would be, (+1) + (+1) + (-1)= +1. Likewise, if the same three participant's 12 month visit showed two with a decrease in leakage and one with no changes in leakage, the outcome would be, (-1) + (-1) + (0)= -2</description>
          <units>Sum of increases (+1) and decreases (-1)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 6 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="-2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Observation</title>
          <description>Observation; No treatment given</description>
        </group>
        <group group_id="E2">
          <title>Intravitreal Ranibizumab 2.0mg</title>
          <description>Initial dose 2.0mg switched to 1.0mg at near conclusion of study.&#xD;
ranibizumab 2.0mg: Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Blood Pressure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Food Poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stiff Neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergies</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Arthur Korotkin, MD</name_or_title>
      <organization>Eye Center of Northern Colorado, PC</organization>
      <phone>970-221-2222</phone>
      <email>retina@eyecenternoco.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

